Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026415 · ClinicalTrials.gov registry record · Phase 1
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT01026415: Completed Phase 1 study, sponsored by Seagen.
NCT01026415 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 73 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026415, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
Interventions
- DRUG brentuximab vedotin
- DRUG midazolam
- DRUG ketoconazole
- DRUG rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
What the finished NCT01026415 record still lists
NCT01026415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 4 interventions - of which brentuximab vedotin is the first listed.
NCT01026415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01026415 about?
NCT01026415 is a clinical study titled "Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)". The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
What is the current status of trial NCT01026415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2009-12. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01026415?
The interventions under investigation include: brentuximab vedotin (DRUG), midazolam (DRUG), ketoconazole (DRUG), rifampin (DRUG).
Who is sponsoring clinical trial NCT01026415?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01026415's enrollment target sits among peer trials
73 732nd of 2000 higher than 1,265 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia